Today's edition · Wednesday, November 18, 2026
Every story verifiedNo politics. Ever.No pop-ups
TodayLocalWorldHeroesAnimalsScienceCommunityHealth & TechMapQuizKindnessAnnouncementsKidsTopicsExplainersOn this dayCalendarGood NeighborHometown Heroes

TodayHealth & TechMaryland

Health & TechSilver Spring, Maryland

The FDA approved the first drug for a rare kidney disease

The FDA approved Gazyva, obinutuzumab, for adults with primary membranous nephropathy at risk of getting worse, to induce remission of protein in the urine. In a 142-person trial, 36 percent reached complete remission at week 104, compared with 6 percent on tacrolimus. It is not a cure.

Verified · Source: U.S. Food and Drug AdministrationNov 13, 2026 · 1 min read
How to help
A scientist in a white coat working with sample tubes at a laboratory bench
Illustrative photo of a medical laboratory. This is not the MAJESTY trial, and the person pictured is not a study doctor. National Institutes of Health. / Wikimedia Commons · Public domain

Read the original

The reporting lives at U.S. Food and Drug Administration. Our summary is checked against it, and we link it on every story.

The Food and Drug Administration approved Gazyva, also called obinutuzumab, for adults with primary membranous nephropathy who are at risk of the disease getting worse. The goal of the approval is to induce remission of proteinuria, protein leaking into the urine. It is the first drug approved specifically for that use in adults. Gazyva was already approved for certain cancers, for active lupus nephritis, and for childhood-onset idiopathic nephrotic syndrome. In the phase 3 MAJESTY trial, 142 adults were randomly assigned to Gazyva or to tacrolimus for 104 weeks. At week 104, 36 percent of the Gazyva group met the study's definition of complete remission, compared with 6 percent of the tacrolimus group. Those figures are for this trial, not for every person with kidney disease. The label carries a boxed warning for hepatitis B reactivation and for a rare brain infection called PML. Common side effects in the study included infusion reactions and upper respiratory infection. The approval is not a cure.

More good news

Other stories in the same neighborhood of kindness.

A row of glass laboratory beakers on a white surfaceHealth & Tech
Silver Spring, Maryland

The FDA approved a pre-surgery bladder cancer combo

The FDA approved durvalumab, sold as Imfinzi, plus enfortumab vedotin before bladder removal, then durvalumab afterward, for muscle-invasive bladder cancer in patients who cannot take cisplatin or who decline it. In the 695-patient VOLGA trial the combo cut the risk of an event by about half. It is not a cure.

Verified · U.S. Food and Drug Administration